ADA 2020: Empagliflozin reduces insulin need in diabetes patients
Written By : Medha Baranwal
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2020-06-17 15:06 GMT | Update On 2020-06-17 15:06 GMT
Advertisement
Delhi: Treatment with the SGLT2 inhibitor empagliflozin reduces dependency on insulin in patients with type 2 diabetes (T2D) and cardiovascular disease (CVD), a recent study has suggested. The findings of the landmark EMPA-REG OUTCOME trial were presented at the American Diabetes Association 80th Scientific Sessions held from June 12-16, 2020.
According to the study, EMPA markedly delayed the need for insulin initiation in those recently diagnosed and reduced the need for large doses in those already on insulin treatment.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.